Comparison of Clopidogrel Monotherapy After 1 to 2 Months of Dual Antiplatelet Therapy With 12 Months of Dual Antiplatelet Therapy in Patients With Acute Coronary Syndrome: The STOPDAPT-2 ACS Randomized Clinical Trial.
Sign Up to like & getrecommendations! Published in 2022 at "JAMA cardiology"
DOI: 10.1001/jamacardio.2021.5244
Abstract: Importance Clopidogrel monotherapy after short dual antiplatelet therapy (DAPT) after percutaneous coronary intervention (PCI) has not yet been fully investigated in patients with acute coronary syndrome (ACS). Objective To test the hypothesis of noninferiority of… read more here.
Keywords: dual antiplatelet; clopidogrel monotherapy; months dapt; antiplatelet therapy ... See more keywords
Safety and preliminary efficacy of argatroban plus dual antiplatelet therapy for acute mild to moderate ischemic stroke with large artery atherosclerosis
Sign Up to like & getrecommendations! Published in 2022 at "Brain and Behavior"
DOI: 10.1002/brb3.2664
Abstract: Previous studies suggest the benefit of dual antiplatelet therapy (DAPT) for acute ischemic stroke with large artery atherosclerosis (LAA) etiology, but there is no study about the effect of DAPT plus anticoagulant in this population. read more here.
Keywords: large artery; antiplatelet therapy; artery atherosclerosis; dual antiplatelet ... See more keywords
Short‐versus long‐term Dual Antiplatelet therapy after drug‐eluting stent implantation in women versus men: A sex‐specific patient‐level pooled‐analysis of six randomized trials
Sign Up to like & getrecommendations! Published in 2017 at "Catheterization and Cardiovascular Interventions"
DOI: 10.1002/ccd.26653
Abstract: Whether the efficacy and safety of dual antiplatelet therapy (DAPT) are uniform between sexes is unclear. We sought to compare clinical outcomes between short‐ (≤6 months) versus long‐term (≥1 year) DAPT after drug‐eluting stent (DES)… read more here.
Keywords: drug eluting; long term; dual antiplatelet; antiplatelet therapy ... See more keywords
Impact of six versus 12 months of dual antiplatelet therapy in patients with drug‐eluting stent implantation after risk stratification with the residual SYNTAX score: Results from a secondary analysis of the I‐LOVE‐IT 2 trial
Sign Up to like & getrecommendations! Published in 2017 at "Catheterization and Cardiovascular Interventions"
DOI: 10.1002/ccd.26948
Abstract: The optimal duration of dual antiplatelet therapy (DAPT) after drug‐eluting stent (DES) implantation remains undetermined, especially for those at high risk of cardiac events postprocedure. read more here.
Keywords: drug eluting; dual antiplatelet; antiplatelet therapy; syntax ... See more keywords
Impact of dual antiplatelet therapy duration on 1‐year clinical outcomes in diabetic patients with acute coronary syndrome undergoing percutaneous coronary intervention: Insights from the real‐world OPT‐CAD study
Sign Up to like & getrecommendations! Published in 2019 at "Catheterization and Cardiovascular Interventions"
DOI: 10.1002/ccd.28653
Abstract: To investigate the optimal dual antiplatelet therapy (DAPT) duration for diabetic patients with acute coronary syndrome (ACS) after percutaneous coronary intervention (PCI). read more here.
Keywords: patients acute; dual antiplatelet; antiplatelet therapy; diabetic patients ... See more keywords
Three versus 12‐month dual antiplatelet therapy duration in patients with acute coronary syndrome undergoing percutaneous coronary intervention: A meta‐analysis of randomized controlled trials
Sign Up to like & getrecommendations! Published in 2022 at "Catheterization and Cardiovascular Interventions"
DOI: 10.1002/ccd.30467
Abstract: The American Heart Association/American College of Cardiology guidelines on dual antiplatelet therapy (DAPT) recommend at least 12 months of a P2Y12 inhibitor and low dose aspirin in patients with an acute coronary syndrome (ACS) treated… read more here.
Keywords: coronary syndrome; randomized controlled; acute coronary; antiplatelet therapy ... See more keywords
Short‐term dual antiplatelet therapy for 1–3 months after percutaneous coronary intervention using drug eluting stents: A systematic review and meta‐analysis of randomized clinical trials
Sign Up to like & getrecommendations! Published in 2022 at "Catheterization and Cardiovascular Interventions"
DOI: 10.1002/ccd.30521
Abstract: The optimal dual antiplatelet therapy (DAPT) duration and regimen in patients undergoing percutaneous coronary intervention (PCI) using current generation drug eluting stents (DES) is still unclear. read more here.
Keywords: drug eluting; percutaneous coronary; eluting stents; coronary intervention ... See more keywords
Changes and innovations of the 2017 ESC guidelines on dual antiplatelet therapy in coronary artery disease—a review
Sign Up to like & getrecommendations! Published in 2018 at "Wiener klinische Wochenschrift"
DOI: 10.1007/s00508-018-1357-5
Abstract: SummaryDuration and compostion of dual antiplatelet therapy has been increasingly changed within the past few years as also indicated in the firmer ESC guidelines. The current manuscript summarizes the most important changes in dual antiplatelet… read more here.
Keywords: changes innovations; esc guidelines; dual antiplatelet; antiplatelet therapy ... See more keywords
Dual antiplatelet therapy in the contemporary drug-eluting stents era: from vulnerable stents to vulnerable patients
Sign Up to like & getrecommendations! Published in 2022 at "Journal of Thrombosis and Thrombolysis"
DOI: 10.1007/s11239-022-02639-z
Abstract: In this issue of the Journal of Thrombosis and Thrombolysis, Dr. Chong and colleagues present a Bayesian network meta-analysis of 15 randomized controlled trials (RCTs) and 43,875 patients in which different DAPT durations, e.g. short… read more here.
Keywords: dual antiplatelet; drug; polymer; antiplatelet therapy ... See more keywords
Influence of CYP2C19 genotypes for the effect of 1-month dual antiplatelet therapy followed by clopidogrel monotherapy relative to 12-month dual antiplatelet therapy on clinical outcomes after percutaneous coronary intervention: a genetic substudy from the STOPDAPT-2
Sign Up to like & getrecommendations! Published in 2020 at "Cardiovascular Intervention and Therapeutics"
DOI: 10.1007/s12928-020-00719-6
Abstract: The ultra-short dual antiplatelet therapy (DAPT) followed by P2Y12 inhibitor monotherapy might be promising after percutaneous coronary intervention (PCI). However, CYP2C19 loss-of-function (LOF) alleles have been reported to diminish the effect of clopidogrel, and clopidogrel… read more here.
Keywords: month dapt; antiplatelet therapy; dual antiplatelet; month ... See more keywords
Toward Brief Dual Antiplatelet Therapy and P2Y12 Inhibitors for Monotherapy After PCI
Sign Up to like & getrecommendations! Published in 2020 at "American Journal of Cardiovascular Drugs"
DOI: 10.1007/s40256-020-00430-0
Abstract: The optimal duration of dual antiplatelet therapy (DAPT) after percutaneous coronary intervention remains a controversial topic. The European Society of Cardiology and the American College of Cardiology/American Heart Association recommend at least 6 and 12… read more here.
Keywords: cardiology; antiplatelet; dual antiplatelet; antiplatelet therapy ... See more keywords